Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Dengue plaque reduction neutralization test (PRNT) in primary and secondary dengue virus infections: How alterations in assay conditions impact performance.

Thomas SJ, Nisalak A, Anderson KB, Libraty DH, Kalayanarooj S, Vaughn DW, Putnak R, Gibbons RV, Jarman R, Endy TP.

Am J Trop Med Hyg. 2009 Nov;81(5):825-33. doi: 10.4269/ajtmh.2009.08-0625.

2.

Variation in dengue virus plaque reduction neutralization testing: systematic review and pooled analysis.

Rainwater-Lovett K, Rodriguez-Barraquer I, Cummings DA, Lessler J.

BMC Infect Dis. 2012 Sep 28;12:233. doi: 10.1186/1471-2334-12-233. Review.

3.

Incorporation of IgG Depletion in a Neutralization Assay Facilitates Differential Diagnosis of Zika and Dengue in Secondary Flavivirus Infection Cases.

Calvert AE, Boroughs KL, Laven J, Stovall JL, Luy BE, Kosoy OI, Huang CY.

J Clin Microbiol. 2018 May 25;56(6). pii: e00234-18. doi: 10.1128/JCM.00234-18. Print 2018 Jun.

4.

Evaluation of chimeric Japanese encephalitis and dengue viruses for use in diagnostic plaque reduction neutralization tests.

Johnson BW, Kosoy O, Hunsperger E, Beltran M, Delorey M, Guirakhoo F, Monath T.

Clin Vaccine Immunol. 2009 Jul;16(7):1052-9. doi: 10.1128/CVI.00095-09. Epub 2009 May 20.

5.

Plaque reduction neutralization antibody test does not accurately predict protection against dengue infection in Ratchaburi cohort, Thailand.

Sirivichayakul C, Sabchareon A, Limkittikul K, Yoksan S.

Virol J. 2014 Mar 12;11:48. doi: 10.1186/1743-422X-11-48.

6.

Evaluation of a Novel Reporter Virus Neutralization Test for Serological Diagnosis of Zika and Dengue Virus Infection.

Shan C, Ortiz DA, Yang Y, Wong SJ, Kramer LD, Shi PY, Loeffelholz MJ, Ren P.

J Clin Microbiol. 2017 Oct;55(10):3028-3036. doi: 10.1128/JCM.00975-17. Epub 2017 Aug 2.

7.

[Investigation of dengue virus and yellow fever virus seropositivities in blood donors from Central/Northern Anatolia, Turkey].

Ergünay K, Saygan MB, Aydoğan S, Litzba N, Niedrig M, Pınar A, Us D.

Mikrobiyol Bul. 2010 Jul;44(3):415-24. Turkish.

PMID:
21063991
8.

Guidelines for Plaque-Reduction Neutralization Testing of Human Antibodies to Dengue Viruses.

Roehrig JT, Hombach J, Barrett AD.

Viral Immunol. 2008 Jun;21(2):123-32. doi: 10.1089/vim.2008.0007. Review.

PMID:
18476771
9.

Comparison of plaque- and enzyme-linked immunospot-based assays to measure the neutralizing activities of monoclonal antibodies specific to domain III of dengue virus envelope protein.

Liu L, Wen K, Li J, Hu D, Huang Y, Qiu L, Cai J, Che X.

Clin Vaccine Immunol. 2012 Jan;19(1):73-8. doi: 10.1128/CVI.05388-11. Epub 2011 Nov 23.

10.

Inferring the serotype associated with dengue virus infections on the basis of pre- and postinfection neutralizing antibody titers.

van Panhuis WG, Gibbons RV, Endy TP, Rothman AL, Srikiatkhachorn A, Nisalak A, Burke DS, Cummings DA.

J Infect Dis. 2010 Oct 1;202(7):1002-10. doi: 10.1086/656141.

12.

Optimization and validation of a plaque reduction neutralization test for the detection of neutralizing antibodies to four serotypes of dengue virus used in support of dengue vaccine development.

Timiryasova TM, Bonaparte MI, Luo P, Zedar R, Hu BT, Hildreth SW.

Am J Trop Med Hyg. 2013 May;88(5):962-970. doi: 10.4269/ajtmh.12-0461. Epub 2013 Mar 4.

13.

Viridot: An automated virus plaque (immunofocus) counter for the measurement of serological neutralizing responses with application to dengue virus.

Katzelnick LC, Coello Escoto A, McElvany BD, Chávez C, Salje H, Luo W, Rodriguez-Barraquer I, Jarman R, Durbin AP, Diehl SA, Smith DJ, Whitehead SS, Cummings DAT.

PLoS Negl Trop Dis. 2018 Oct 24;12(10):e0006862. doi: 10.1371/journal.pntd.0006862. eCollection 2018 Oct.

14.

Dengue virus infections in a cohort of schoolchildren from Maracay, Venezuela: a 2-year prospective study.

Comach G, Blair PJ, Sierra G, Guzman D, Soler M, de Quintana MC, Bracho-Labadie M, Camacho D, Russell KL, Olson JG, Kochel TJ.

Vector Borne Zoonotic Dis. 2009 Feb;9(1):87-92. doi: 10.1089/vbz.2007.0213. Epub 2008 Sep 12.

PMID:
18788903
15.

[Flavivirus seroepidemiology in blood donors in Mersin province, Turkey].

Tezcan S, Kızıldamar S, Ulger M, Aslan G, Tiftik N, Ozkul A, Emekdaş G, Niedrig M, Ergünay K.

Mikrobiyol Bul. 2014 Oct;48(4):606-17. Turkish.

16.

Correlation between dengue-specific neutralizing antibodies and serum avidity in primary and secondary dengue virus 3 natural infections in humans.

Puschnik A, Lau L, Cromwell EA, Balmaseda A, Zompi S, Harris E.

PLoS Negl Trop Dis. 2013 Jun 13;7(6):e2274. doi: 10.1371/journal.pntd.0002274. Print 2013.

17.

Optimization of the cutoff value for a commercial anti-dengue virus IgG immunoassay.

Marrero-Santos KM, Beltrán M, Carrión-Lebrón J, Sanchez-Vegas C, Hamer DH, Barnett ED, Santiago LM, Hunsperger EA.

Clin Vaccine Immunol. 2013 Mar;20(3):358-62. doi: 10.1128/CVI.00429-12. Epub 2013 Jan 9.

18.

Dengue virus serotype distribution based on serological evidence in pediatric urban population in Indonesia.

Sasmono RT, Taurel AF, Prayitno A, Sitompul H, Yohan B, Hayati RF, Bouckenooghe A, Hadinegoro SR, Nealon J.

PLoS Negl Trop Dis. 2018 Jun 28;12(6):e0006616. doi: 10.1371/journal.pntd.0006616. eCollection 2018 Jun.

19.

Discrepancy in dengue virus neutralizing antibody titers between plaque reduction neutralizing tests with Fcgamma receptor (FcgammaR)-negative and FcgammaR-expressing BHK-21 cells.

Moi ML, Lim CK, Kotaki A, Takasaki T, Kurane I.

Clin Vaccine Immunol. 2010 Mar;17(3):402-7. doi: 10.1128/CVI.00396-09. Epub 2009 Dec 30.

20.

Recombinant envelope protein-based enzyme immunoassay for IgG antibodies is comparable to neutralization tests for epidemiological studies of dengue infection.

Rocha ES, Oliveira JG, Santos JR, Rodrigues GO, Figueiredo LB, Pessanha JE, Proietti FA, Fonseca FG, Bonjardim CA, Ferreira PC, Kroon EG.

J Virol Methods. 2013 Jan;187(1):114-20. doi: 10.1016/j.jviromet.2012.09.012. Epub 2012 Sep 24.

Supplemental Content

Support Center